Abstract
The review is devoted to inhibition of the complement anaphylatoxin activities in diseases of the central nervous system. Here we present epidemiological data on the prevalence of cerebrovascular diseases, in particular, ischemic stroke and craniocerebral trauma. The mechanisms of complement activation and complement-mediated pathology in the central nervous system are considered in detail. Clinical data confirming the role of the complement system in the pathogenesis of stroke and of traumatic brain injury secondary injury are presented. We also summarize the results of in vivo specific activity studies of the complement anaphylatoxin inhibitors using animal models of stroke and traumatic brain injury. Briefly described is the present state of the art in developing drugs that target the effector compounds of the complement cascade.
Reference92 articles.
1. Piradov MA, Maksimova MYu, Tanashyan MM. Stroke. Step-by-step instruction. Moscow: GEOTAR-Media; 2019. (In Russ.)
2. The Stroke Riskometer™ App: Validation of a Data Collection Tool and Stroke Risk Predictor
3. Gusev EI, Konovalov AN, Skvortsova VI. Neurology and neurosurgery: textbook: v 2 t. Ed. by A.N. Konovalova, A.V. Kozlova. Moscow: GEOTAR-Media; 2009. Vol. 2. (In Russ.)
4. Inflammation in neurodegenerative diseases
5. Innate immunity and brain inflammation: the key role of complement